As of 6 Nov 2026, Zenlabs Ethica is loss-making on a trailing 12-month basis, with a net loss of ₹2.54 Cr, so it has no P/E ratio. The share price is ₹25.50, 36% below its 52-week high. Sales fell 11% a year over 3 years. Debt is 1.29× equity. It is a small-cap company with a market cap of ₹17 Cr, ranked 9th of 11 Medical Distribution companies by market cap; the shares fell 15% over the past year.
- ₹27.46
- ₹27.46
- ₹25.08
- ₹27.22
- 35
Health check
- ReturnsBehind
−14.9% over a year, better than 2 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −11.1% a year over 3 years.
- ProfitabilityNegative
ROCE -10.1% vs peer median 9.4%.
- Balance sheetStretched
Debt 1.29× equity, operating profit doesn’t cover interest, Piotroski 4 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹17 Cr
- Small cap
- P/E
- n/a
- Industry 36.7
- Price to book
- 1.97
- Peers 2.10
- Dividend yield
- 0.00%
- ROE
- −20.4%
- Peers 8.0%
- ROCE
- −10.1%
- Peers 9.4%
- Debt to equity
- 1.29
- Debt ₹11 Cr
- EPS (TTM)
- −₹3.90
- OPM (TTM)
- 1.9%
- Net margin −5.1%
- Sales growth
- +23.5%
- Latest quarter vs a year ago
- Profit growth
- −1815.3%
- Latest quarter vs a year ago
- Price to sales
- 0.33
- EV/EBITDA 19.3
Strengths and risks
Strengths
- Quarterly sales up 23.5% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −20.4%.
- Quarterly profit down 1815.3% on a year ago.
- 36% below its 52-week high.
- Interest coverage of only 2.5×.
About Zenlabs Ethica
Zenlabs Ethica Limited markets and distributes pharmaceutical products in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic…
- Headquarters
- Chandigarh
- Employees
- 66
- Sector
- Healthcare
- ISIN
- INE546F01013
- Website
- zenlabsethica.com
Price range
- Avg volume (3M)
- 2.1K
- 1-year return
- minus 14.9%
- From 52-week high
- minus 36.2%
Peers · Medical Distribution
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTEROEntero Healthcare Solutions | 1,900.40 | plus 8.34% | 8,279 | 66.0 | 4.90 | 11.3% | 6.7% | 4.4% | 25.7% | – | 0.00% | plus 62.4% |
| APPLAptus Pharma | 465.00 | plus 0.92% | 797 | 100.2 | 28.06 | 29.3% | 31.7% | 15.4% | 49.6% | 187.5% | 0.00% | plus 772.6% |
| ARVAYAArvaya Healthcare | 111.00 | minus 4.31% | 576 | – | – | 1.4% | 2.2% | 0.0% | 193.6% | – | 0.00% | plus 143.1% |
| EVEXIAEvexia Lifecare | 1.46 | minus 3.31% | 274 | 146.0 | 0.67 | 0.3% | 0.3% | 1.6% | 16.6% | 34.5% | 0.00% | minus 15.2% |
| NOVELIXNovelix Pharmaceuticals | 64.66 | minus 4.91% | 184 | 36.7 | 2.93 | 7.4% | 8.0% | 3.1% | 354.8% | – | 0.00% | plus 29.5% |
| AMWILLAmwill Health Care | 44.00 | plus 5.67% | 88 | 7.8 | 1.06 | 15.5% | 14.4% | 14.1% | 14.7% | 54.2% | 2.27% | minus 25.4% |
| CBPLChandra Bhagat Pharma | 55.50 | minus 4.31% | 42 | 13.7 | 1.26 | – | 9.7% | 2.5% | – | – | 0.00% | plus 45.0% |
| ZENLABSZenlabs Ethica | 25.50 | minus 6.32% | 17 | – | 1.97 | −10.1% | −20.4% | 1.9% | −11.1% | – | 0.00% | minus 14.9% |
| Median of 7 peers | – | −3.31% | 274 | 51.4 | 2.10 | 9.4% | 8.0% | 3.1% | 37.7% | 54.2% | 0.00% | 45.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 11.5 | 12.4 | 12.4 | 10.6 | 14.2 | |
| 10.9 | 12 | 11.9 | 10.3 | 14.5 | |
| 0.5 | 0.4 | 0.5 | 0.3 | −0.3 | |
| 4.7% | 3.6% | 4.1% | 2.7% | −2.1% | |
| 0 | 0.1 | 0 | 0.1 | 0 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
| 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | |
| – | – | −2.1 | – | – | |
| 0 | 0.1 | −2 | 0.1 | −0.6 | |
| 25.2% | 51.9% | 0.3% | 98.6% | −2.8% | |
| 0 | 0 | −2 | 0 | −0.6 | |
| 0.05 | 0.06 | -3.08 | – | -0.88 |
Profit & loss
- Sales CAGR 3Y
- −11.1%
- ROE
- −20.4%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 66.9 | 58.6 | 51.4 | 46.9 | |
| – | minus 12.4% | minus 12.2% | minus 8.8% | |
| 64 | 56.2 | 48.8 | 45 | |
| 2.9 | 2.4 | 2.6 | 2 | |
| 4.3% | 4.1% | 5.0% | 4.2% | |
| 0.1 | 0.1 | 0 | 0.1 | |
| 0.5 | 0.8 | 0.9 | 0.8 | |
| 1.3 | 1.3 | 1.3 | 0.9 | |
| −0.6 | 0.2 | 0 | −2.2 | |
| 0.7 | 0.6 | 0.4 | −1.8 | |
| 27.5% | 27.6% | 37.1% | −6.8% | |
| 0.5 | 0.4 | 0.3 | −1.9 | |
| – | minus 13.9% | minus 36.1% | minus 819.0% | |
| 0.75 | 0.65 | 0.41 | -2.97 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 6.5 | 6.5 | 6.5 | 6.5 | |
| 3.2 | 3.6 | 3.9 | 2 | |
| 5.8 | 14.9 | 12.7 | 11 | |
| 27.9 | 15.3 | 17.5 | 17.7 | |
| 43.5 | 40.3 | 40.6 | 37.2 | |
| 5 | 3.7 | 2.3 | 1.9 | |
| 0.7 | 0.7 | 0.7 | – | |
| 0.1 | 0.9 | 1.8 | 2.9 | |
| 37.7 | 35 | 35.8 | 32.4 | |
| 43.5 | 40.3 | 40.6 | 37.2 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1.5 | −9.1 | 3.8 | 4.1 | |
| −1.5 | 0.1 | 0.1 | 0 | |
| 0.1 | 8.2 | −3.1 | −3 | |
| 0.1 | −0.7 | 0.9 | 1.1 | |
| −1.5 | −0 | −0 | −0 | |
| −0 | −9.1 | 3.8 | 4.1 | |
| −0.2 | – | – | – |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.